Description
Atirmociclib is an investigational drug currently being studied in clinical trials for certain types of cancer. In colorectal cancer (CRC) trials, it is being investigated in combination with other drugs. The trials are in early phases (Phase 1), meaning they primarily focus on determining the safety and appropriate dosage of the drug, often in patients who have not responded to standard treatments. The goal is to see if the combination is safe and if it shows any signs of effectiveness. It is being studied in patients with specific genetic mutations, such as HER2 or MET mutations, or KRAS wild-type tumors. Atirmociclib is not yet approved for treating CRC.
Mechanism of Action
Atirmociclib is a type of drug that targets specific proteins involved in cell growth and division. It belongs to a class of drugs called cyclin-dependent kinase (CDK) inhibitors. By inhibiting these CDKs, atirmociclib aims to stop or slow down the growth of cancer cells. The specific molecular target is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.